USA flag logo/image

An Official Website of the United States Government

Bacteriophage-based probiotic preparation for managing Shigella infections

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
Program Year/Program:
2011 / STTR
Agency Tracking Number:
A2-4117
Solicitation Year:
2009
Solicitation Topic Code:
A09A-T012
Solicitation Number:
2009.A
Small Business Information
INTRALYTIX INC
351 W CAMDEN ST STE 100 Baltimore, MD 21201-8603
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2011
Title: Bacteriophage-based probiotic preparation for managing Shigella infections
Agency / Branch: DOD / ARMY
Contract: W911NF-11-C-0074
Award Amount: $749,969.00
 

Abstract:

During the studies supported by our Phase I STTR grant from the US Army, we began developing and testing a novel concept for a probiotic preparation based on naturally occurring bacteriophages as a way to condition the GI tract"s microflora gently and favorably. The preparation (tentatively designated"ShigActive") is a bacteriophage cocktail that specifically targets Shigella spp. (significant diarrhea-causing pathogens that sicken ca. 165 million people/year, ca. 1.1 million of whom die). We have succesfully isolated and rigorously characterized a large number of phages lytic for Shigella, and we have developed a murine model in which the in vivo efficacy of our phage preparation can be evaluated. During this Phase II project, we propose to perform studies required to obtain regulatory approval of ShigActive. During these studies, we will also perform metagenomic analyses of the gut microbiota (using DGGE and state-of-the-art 454-pyrosequencing of 16S rRNA genes) of mice before and after their treatment with ShigActive, in order to (i) obtain additional safety data for the FDA, and (ii) compare rigorously the effect of ShigActive and ampicillin (an antibiotic commonly used to treat shigellosis) on the intestinal microflora of mice. The proposed project"s primary goal is to submit a New Dietary Ingredient (NDI) Notification to the FDA, whose approval will enable us to commence commercial sales of ShigActive.

Principal Investigator:

Alexander Sulakvelidze
Chief Scientist
(410) 625-2533
asulakvelidze@intralytix.com

Business Contact:

John Woloszyn
President and CEO
(410) 625-3813
jwoloszyn@intralytix.com
Small Business Information at Submission:

Intralytix, Inc.
The Columbus Center 701 E. Pratt Street Baltimore, MD 21202-

EIN/Tax ID: 522112466
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
University of Florida
Division of Sponsored Programs
219 Grinter Hall
Gainesville, FL 23611-
Contact: Brian Prindle
Contact Phone: (352) 392-3516